-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Versigent, Raises Price Target to $58

Benzinga·06/05/2026 19:04:06
Listen to the news
UBS analyst Joseph Spak maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $49 to $58.